mixed cell type kidney Wilms' tumor

Summary

mixed cell type kidney Wilms’ tumor (MONDO:0003318) is a cancer and 1 clinical trial. Top therapeutic interventions include cyclophosphamide anhydrous and dactinomycin. A subtype of kidney Wilms tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mixed cell type kidney Wilms’ tumor
Mondo ID	MONDO:0003318
DOID	DOID:5179
NCIT	C9149
UMLS	C0279611
MedGen	76001
GARD	0023445
Is cancer (heuristic)	yes

Also known as: mixed cell type kidney adenosarcoma · mixed cell type kidney Wilms tumor · mixed cell type kidney Wilms tumour · mixed cell type nephroblastoma · mixed cell type renal adenosarcoma · mixed cell type renal Wilm’s tumor · mixed cell type renal Wilm’s tumour · mixed cell type renal Wilms tumor · mixed cell type renal Wilms’ tumor · mixed cell type renal Wilms’ tumour · Mixed cell type Wilms tumor · Mixed cell type Wilms tumour

Disease family

This is a subtype of kidney Wilms tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › kidney cancer › kidney Wilms tumor › mixed cell type kidney Wilms’ tumor

Related subtypes (7): nonanaplastic kidney Wilms tumor, metachronous kidney Wilms’ tumor, blastema predominant kidney Wilms tumor, epithelial predominant Wilms’ tumor, stromal predominant kidney Wilms tumor, adult kidney Wilms tumor, childhood kidney Wilms tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06401330	PHASE3	RECRUITING	A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	1
DACTINOMYCIN	4	1
CHEMBL4748391	0	1